WHO ICTRP trial
PHASE II STUDY OF IMATINIB MESYLATE IN CHORDOMA
EUCTR2004-001362-40-IT · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2004-001362-40-IT |
|---|---|
| Public title | PHASE II STUDY OF IMATINIB MESYLATE IN CHORDOMA |
| Scientific title | PHASE II STUDY OF IMATINIB MESYLATE IN CHORDOMA |
| Primary sponsor | NOVARTIS FARMA |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Italy |
| Conditions | Treatment of advanced or unresectable chordoma MedDRA version: 6.1 Level: PT Classification code 10008747 |
| Interventions | Product Name: IMATINIB Product Code: STI571 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Imatinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- |
| Registration date | Jun 16, 2005 |
| Secondary IDs | CSTI571BIT15 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: